kirsten harkins 2015 cadth symposium april 13, 2015 saskatoon, sk daring to be rare: striving to...
TRANSCRIPT
![Page 1: KIRSTEN HARKINS 2015 CADTH SYMPOSIUM APRIL 13, 2015 SASKATOON, SK Daring to be Rare: Striving to Meet the Needs of Patients with Rare Diseases](https://reader036.vdocuments.site/reader036/viewer/2022082816/56649d355503460f94a0c8b9/html5/thumbnails/1.jpg)
KIRSTEN HARKINS
2015 CADTH SYMPOSIUMAPRIL 13 , 2015SASKATOON, SK
Daring to be Rare: Striving to Meet the Needs of Patients with Rare Diseases
![Page 2: KIRSTEN HARKINS 2015 CADTH SYMPOSIUM APRIL 13, 2015 SASKATOON, SK Daring to be Rare: Striving to Meet the Needs of Patients with Rare Diseases](https://reader036.vdocuments.site/reader036/viewer/2022082816/56649d355503460f94a0c8b9/html5/thumbnails/2.jpg)
March 2001: Nicklas diagnosed with MPS I
![Page 3: KIRSTEN HARKINS 2015 CADTH SYMPOSIUM APRIL 13, 2015 SASKATOON, SK Daring to be Rare: Striving to Meet the Needs of Patients with Rare Diseases](https://reader036.vdocuments.site/reader036/viewer/2022082816/56649d355503460f94a0c8b9/html5/thumbnails/3.jpg)
August 2003: Nicklas’s first infusion
![Page 4: KIRSTEN HARKINS 2015 CADTH SYMPOSIUM APRIL 13, 2015 SASKATOON, SK Daring to be Rare: Striving to Meet the Needs of Patients with Rare Diseases](https://reader036.vdocuments.site/reader036/viewer/2022082816/56649d355503460f94a0c8b9/html5/thumbnails/4.jpg)
A journey into patient advocacy
“We are both burdened and blessed by the great responsibility of free will – the power of choice. Our future is determined, in large part, by the choices we make now. We cannot always control our circumstances, but we can and do choose our own response to whatever arises. Reclaiming the power of choice, we find the courage to live fully in the world.”
- Dan Millman, The Laws of Spirit: Tales of Transformation
![Page 5: KIRSTEN HARKINS 2015 CADTH SYMPOSIUM APRIL 13, 2015 SASKATOON, SK Daring to be Rare: Striving to Meet the Needs of Patients with Rare Diseases](https://reader036.vdocuments.site/reader036/viewer/2022082816/56649d355503460f94a0c8b9/html5/thumbnails/5.jpg)
The early days of advocacy
2004: CDR recommend against funding Aldurazyme
There was no avenue for patient input in the process
2005: Rare disease patients demanded to be heard
![Page 6: KIRSTEN HARKINS 2015 CADTH SYMPOSIUM APRIL 13, 2015 SASKATOON, SK Daring to be Rare: Striving to Meet the Needs of Patients with Rare Diseases](https://reader036.vdocuments.site/reader036/viewer/2022082816/56649d355503460f94a0c8b9/html5/thumbnails/6.jpg)
Realizing collaboration is the key
Working together essential for successCanadian MPS Society; International MPS
NetworkCORD; Rare Disease Foundation (RDF)Working with provincial health ministries
when federal government failed to create rare disease programs (eg: Elaprase for MPS II was pilot drug for Ontario’s Drugs for Rare Diseases program)
Building bridges and learning how to work with all stakeholders in a passionate, but educated, sophisticated and reasonable fashion
![Page 7: KIRSTEN HARKINS 2015 CADTH SYMPOSIUM APRIL 13, 2015 SASKATOON, SK Daring to be Rare: Striving to Meet the Needs of Patients with Rare Diseases](https://reader036.vdocuments.site/reader036/viewer/2022082816/56649d355503460f94a0c8b9/html5/thumbnails/7.jpg)
Patient involvement: Patient Centred Care
2012: Health Minister’s announcement of a new rare disease framework, which would involve patients as partners in rare disease care
CIHR funded grants to figure out how to integrate rare disease treatments into the Canadian healthcare system
CDR initiated patient input process – huge step forward! (But questions remain as to the weighting and the capacity of small organizations to create strong submissions on lean budgets)
PRISM: patient advocates on advisory panel
![Page 8: KIRSTEN HARKINS 2015 CADTH SYMPOSIUM APRIL 13, 2015 SASKATOON, SK Daring to be Rare: Striving to Meet the Needs of Patients with Rare Diseases](https://reader036.vdocuments.site/reader036/viewer/2022082816/56649d355503460f94a0c8b9/html5/thumbnails/8.jpg)
Meaningful involvement
Integrating patient input to the process is important, but not easy!
Opportunities for inclusion: Research grant funding Registries & data collection Clinical trial development (ie: meaningful endpoints – MPS IVA
pain example; trial design; protocol advice; increased inclusion) Risk assessment; assessing benefits vs harms Guideline development Treatment value: take patients’ and their families’ experiences
seriously! Rare diseases affect families & societies, as do treatments
TRANSPARENCY is crucial as we deal with uncertainty; life-cycle approach & post-market analysis necessary
![Page 9: KIRSTEN HARKINS 2015 CADTH SYMPOSIUM APRIL 13, 2015 SASKATOON, SK Daring to be Rare: Striving to Meet the Needs of Patients with Rare Diseases](https://reader036.vdocuments.site/reader036/viewer/2022082816/56649d355503460f94a0c8b9/html5/thumbnails/9.jpg)
Remember why we’re here!
“Aerodynamically, the dragonfly
shouldn’t be able to fly, but the
dragonfly doesn’t care, so it just goes on flying anyway.”
These kids are fearless.
What are we afraid of?